A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer
Standard
A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. / Köcher, S; Beyer, B; Lange, T; Nordquist, L; Volquardsen, J; Burdak-Rothkamm, S; Schlomm, T; Petersen, C; Rothkamm, K; Mansour, W Y.
in: INT J CANCER, Jahrgang 144, Nr. 7, 01.04.2019, S. 1685-1696.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer
AU - Köcher, S
AU - Beyer, B
AU - Lange, T
AU - Nordquist, L
AU - Volquardsen, J
AU - Burdak-Rothkamm, S
AU - Schlomm, T
AU - Petersen, C
AU - Rothkamm, K
AU - Mansour, W Y
N1 - © 2018 UICC.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Here, we present a functional assay to detect the repair switch to the alternative PARP1-dependent end joining (PARP1-EJ) pathway and the associated susceptibility to PARPi-mediated radiosensitization in freshly collected tumor samples from prostate cancer (PCa) patients, thereby facilitating the selection of patients who should benefit from combined PARPi plus radiotherapy (RT) treatment. Our optimized ex-vivo approach sustains tumor slices for up to 15 days under culture conditions that maintain proliferation and oxygenation rates, as measured by EdU incorporation and pimonidazole staining, respectively. We present a robust system to analyze DSB repair using, for the first time in an ex vivo tumor slice setting, two DSB-markers simultaneously i.e. γH2AX and 53BP1. A computer-based processing method (i) controls variations in DNA content and slicing on the number of repair foci and (ii) measures the PARPi-mediated enhancement ratio on DSB foci numbers to ensure inter-patient-comparability. We validated this approach using a PC3 xenograft model with its previously described repair switch to PARP1-EJ. More importantly, we show that approximately 30% of the analyzed tumor tissue samples collected from PCa patients display a switch to PARP1-EJ, as indicated by the enhanced number of residual γH2AX/53BP1 foci exclusively after PARPi+RT. Furthermore, normal prostatic tissues show no repair switch to PARP1-EJ, indicating that this repair switch and its associated radiosensitizing effect is tumor-specific. Collectively, we present here a predictive assay for the switch to PARP1-EJ that enables individualization of anti-cancer treatment using a combination of RT and radiosensitizing anticancer agents such as PARPi in PCa.
AB - Here, we present a functional assay to detect the repair switch to the alternative PARP1-dependent end joining (PARP1-EJ) pathway and the associated susceptibility to PARPi-mediated radiosensitization in freshly collected tumor samples from prostate cancer (PCa) patients, thereby facilitating the selection of patients who should benefit from combined PARPi plus radiotherapy (RT) treatment. Our optimized ex-vivo approach sustains tumor slices for up to 15 days under culture conditions that maintain proliferation and oxygenation rates, as measured by EdU incorporation and pimonidazole staining, respectively. We present a robust system to analyze DSB repair using, for the first time in an ex vivo tumor slice setting, two DSB-markers simultaneously i.e. γH2AX and 53BP1. A computer-based processing method (i) controls variations in DNA content and slicing on the number of repair foci and (ii) measures the PARPi-mediated enhancement ratio on DSB foci numbers to ensure inter-patient-comparability. We validated this approach using a PC3 xenograft model with its previously described repair switch to PARP1-EJ. More importantly, we show that approximately 30% of the analyzed tumor tissue samples collected from PCa patients display a switch to PARP1-EJ, as indicated by the enhanced number of residual γH2AX/53BP1 foci exclusively after PARPi+RT. Furthermore, normal prostatic tissues show no repair switch to PARP1-EJ, indicating that this repair switch and its associated radiosensitizing effect is tumor-specific. Collectively, we present here a predictive assay for the switch to PARP1-EJ that enables individualization of anti-cancer treatment using a combination of RT and radiosensitizing anticancer agents such as PARPi in PCa.
KW - Journal Article
KW - Prostatic Neoplasms/genetics
KW - Tissue Culture Techniques
KW - Humans
KW - Male
KW - DNA Breaks, Double-Stranded
KW - Histones/metabolism
KW - Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage
KW - Poly (ADP-Ribose) Polymerase-1/antagonists & inhibitors
KW - Animals
KW - Neoplasm Grading
KW - Radiation-Sensitizing Agents/administration & dosage
KW - Tumor Suppressor p53-Binding Protein 1/metabolism
KW - Cell Line, Tumor
KW - Mice
KW - Cell Proliferation/drug effects
KW - DNA End-Joining Repair/drug effects
U2 - 10.1002/ijc.32018
DO - 10.1002/ijc.32018
M3 - SCORING: Journal article
C2 - 30478958
VL - 144
SP - 1685
EP - 1696
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 7
ER -